This is a StreetInsider.com Premium Only Page

Madrigal Pharma (MDGL) –

Apr 23, 2024 08:00 AM Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

Apr 22, 2024 09:34 AM BofA Securities Starts Madrigal Pharmaceuticals (MDGL) at Underperform, 'pivoting to Rezdiffra commercial dynamics'

Apr 16, 2024 04:05 PM Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 9, 2024 08:01 AM Madrigal Pharma (MDGL) Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Apr 9, 2024 08:00 AM Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Apr 9, 2024 08:00 AM Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Apr 3, 2024 04:05 PM Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 19, 2024 02:50 PM Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'

Mar 19, 2024 12:02 AM Madrigal Pharma (MDGL) Announces Pricing of Upsized $600 Million Public Offering

Mar 18, 2024 11:58 PM Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Mar 18, 2024 04:04 PM Madrigal Pharma (MDGL) Announces Proposed $500M Public Offering

Mar 18, 2024 04:04 PM Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)

Mar 18, 2024 04:04 PM Madrigal Pharmaceuticals Announces Proposed Public Offering

Mar 18, 2024 06:10 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $565 at Goldman Sachs

Mar 15, 2024 11:35 AM Midday movers: Adobe, Zillow fall; Micron rises

Mar 15, 2024 10:38 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $410 at UBS

Mar 15, 2024 08:26 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $397 at JMP Securities, ' We had strong conviction'

Mar 15, 2024 07:52 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $400 at Jefferies, 'label hit our bull case'

Mar 15, 2024 07:37 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $375 at Oppenheimer

Mar 15, 2024 06:54 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $390 at TD Cowen

Mar 15, 2024 06:49 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $377 at Canaccord Genuity

Mar 15, 2024 06:11 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'

Mar 15, 2024 04:13 AM B.Riley Upgrades Madrigal Pharmaceuticals (MDGL) to Neutral

Mar 15, 2024 03:49 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $389 at Citi

Mar 15, 2024 03:48 AM Madrigal Pharma (MDGL) option IV into FDA approves Madrigal Pharmaceuticals' Rezdiffra

Mar 14, 2024 04:48 PM After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain

Mar 14, 2024 04:16 PM Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Mar 14, 2024 04:15 PM Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosi

Mar 14, 2024 03:52 PM Madrigal Pharma (MDGL): FDA Approves rezdiffra

Mar 14, 2024 03:51 PM Madrigal Pharma (MDGL) option implied volatility into FDA approval

Mar 14, 2024 03:45 PM Madrigal Gets FDA Approval For NDA For Rezdiffra

Mar 14, 2024 03:30 PM Madrigal Pharma (MDGL) Halted, News Pending

Mar 12, 2024 06:14 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at H.C. Wainwright

Mar 8, 2024 07:30 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $338 at Canaccord Genuity

Mar 6, 2024 04:05 PM Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2024 03:58 AM Citi Starts Madrigal Pharmaceuticals (MDGL) at Buy, Opens 30-Day Upside Catalyst Watch

Mar 5, 2024 08:04 AM Madrigal Pharma (MDGL) Announces EMA Validation of its Marketing Authorization Application for Resmetirom

Mar 5, 2024 08:00 AM Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Mar 1, 2024 05:58 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $320 at Oppenheimer

Feb 28, 2024 07:32 AM Madrigal Pharma (MDGL) Misses Q4 EPS by 44c

Feb 28, 2024 07:01 AM Madrigal Pharma (MDGL) Appoints Mardi C. Dier as CFO

Feb 28, 2024 07:01 AM Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

Feb 28, 2024 07:00 AM Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024 10:12 AM B.Riley Downgrades Madrigal Pharmaceuticals (MDGL) to Sell

Feb 21, 2024 08:00 AM Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Feb 9, 2024 03:39 AM Madrigal Pharmaceuticals (MDGL) PT Lowered to $347 at JMP Securities

Feb 8, 2024 08:01 AM Madrigal Pharma (MDGL) Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom

Feb 8, 2024 08:00 AM Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Feb 6, 2024 04:05 PM Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 29, 2024 08:04 AM Madrigal Pharma (MDGL) Announces Leadership Changes